AstraZeneca ADR


SKU: AZN-1 Category:


AstraZeneca PLC: How Will Its Expansion In Vaccines & Cell Therapy Play Out?


Based on the Q1 2024 results earnings call for AstraZeneca, the British multinational pharmaceutical and biopharmaceutical company seems to be on a steady growth trajectory, but like all corporations, it’s not without its risks. In terms of its achievements, AstraZeneca reported its first quarter of 2024 with a 19% growth in total revenue, reflecting high demand for its products. Core earnings per share rose by 13%. The revenue growth was most pronounced across AstraZeneca’s therapy areas, with both its Oncology and BioPharma businesses exceeding $5 billion in quarterly revenue for the first time. Rare Disease also exceeded $2 billion, showcasing the high value that AstraZeneca’s medicines bring to patients worldwide.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!